SCHEMBL5771308

SCHEMBL5771308

NC(=O)c1cccc2c1c1c(O)c3ccccc3cc1n2Cc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G10 O15496 2/20 0.43
PARP1 P09874 2/20 0.43
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 3/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
PLA2G2A P14555 3/20 0.42
POLB P06746 2/20 0.42
CNR2 P34972 1/20 0.42
RECQL P46063 1/20 0.42
CASP6 P55212 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CCR2 P41597 3/20 0.42
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CYP19A1 P11511 1/20 0.41
GAA P10253 1/20 0.41
P2RX4 Q99571 1/20 0.41
NPC1 O15118 1/20 0.41
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5772908 0.91 CCR2 (0.47) ALDH1A1KDM4EMEN1KMT2APOLB
SCHEMBL5768372 0.83 PLA2G2A (0.46) PLA2G10PLA2G2APLA2G1BPLA2G2EPLA2G2D
SCHEMBL5212989 0.80 PLA2G2A (0.58) PLA2G10PARP1ALDH1A1KDM4EMEN1
SCHEMBL6694433 0.79 PLA2G2A (0.46) PLA2G10PARP1ALDH1A1KDM4EMEN1
SCHEMBL5767057 0.78 FABP4 (0.46) PARP1MEN1KMT2APLA2G2AFABP4
SCHEMBL6690357 0.78 PLA2G2A (0.51) PLA2G10ALDH1A1MEN1KMT2APLA2G2A
SCHEMBL8575180 0.78 PLA2G2A (0.46) PLA2G10PARP1PLA2G2ACYP19A1PLA2G1B
SCHEMBL6984365 0.78 PLA2G2A (0.55) ALDH1A1KDM4EMEN1KMT2APLA2G2A
SCHEMBL6777696 0.77 PLA2G2A (0.47) PLA2G10PARP1PLA2G2APLA2G1BPLA2G2E
SCHEMBL6309980 0.77 PLA2G2A (0.60) PLA2G10PLA2G2APLA2G1BPLA2G2EPLA2G2D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1349836-B1 TETRACYCLIC DERIVATIVES AS SPLA2 INHIBITORS LILLY CO ELI (US) 2006-06-14 EP disclosed
US-6992100-B2 sPLA2 inhibitors ELI LILLY AND COMPANY (US) 2006-01-31 US disclosed
US-20040092543-A1 Novel spla2 inhibitors BEIGHT DOUGLAS WADE (US) 2004-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092543-A1 Novel spla2 inhibitors PLA2G12A, PLAAT2, SPINT2 PLA2G10 15/4885PARP1 3452/4885ALDH1A1 3868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.